经肝动脉插管栓塞化疗原发性肝癌的临床观察  

The clinical observation of hepatic artery chemoembolization of primary liver cancer

作　　者：陈中安[1] 

机构地区：[1]四川省邻水县人民医院CT室,四川邻水638500

出　　处：《医学影像学杂志》2011年第10期1498-1500,共3页Journal of Medical Imaging

摘　　要：目的:了解原发性肝癌的经肝动脉插管栓塞化疗的方法,探讨经肝动脉插管栓塞化疗原发性肝癌的临床疗效。方法:对28例原发性肝癌患者临床使用经肝动脉插管栓塞化疗的临床资料进行回顾性分析,比较其AFP,AST,γ-GT及TBiL等指标的变化,统计其生存率及平均生存时间等临床疗效。结果:患者治疗前和治疗后1个月的AFP,AST,γ-GT及TBiL指标相比存在显著统计差异,P<0.05。结论:使用经肝动脉插管栓塞化疗对原发性肝癌进行治疗,其近期疗效比较稳定,副作用小,患者生存率高,平均生存时间比较长,是一种比较实用的治疗方法。Objective： Knowing primary liver cancer by hepatic artery chemoembolization method of the hepatic artery chemoembolization of the clinical efficacy. Methods： Analyzing clinical data of 28 cases of primary liver cancer patients by using of clinical hepatic artery embolization retrospectively, then compare the AFP, AST, 7-GT and TBiL other indicators of changes, the survival rate and average survival statistics time of clinical efficacy. Results：Compared patients＇ AFP, AST, 7-GT and TBiL indicators one month after the treatment were significant statistical differences than before, P〈0. 05. Conclusion.. Hepatic artery chemoembolization for treatment of primary liver cancer is more stable, less side effects, high survival rate, the average survival time is longer, which is a more practical method of treatment.

关 键 词：原发性肝癌 经肝动脉插管栓塞化疗 

分 类 号：R735[医药卫生—肿瘤] R815[医药卫生—临床医学]